The ROE as of September 2024 (TTM) for Inhibrx, Inc. (INBX) is 1.62%

According to Inhibrx, Inc.’s latest financial reports and current stock price. The company's current ROE is 1.62%. This represents a change of -7407.14% compared to the average of -22.14% of the last 4 quarters.

Inhibrx, Inc. (INBX) Historical ROE (quarterly & annually)

How has INBX ROE performed in the past?

The mean historical ROE of Inhibrx, Inc. over the last ten years is -99.41%. The current 1.62% ROE has changed -1727.21% with respect to the historical average. Over the past ten years (40 quarters), INBX's ROE was at its highest in in the June 2024 quarter at 846.99%. The ROE was at its lowest in in the March 2024 quarter at -680.41%.

Inhibrx, Inc. (INBX) ROE by Quarter and Year

Discovering the peaks and valleys of Inhibrx, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Inhibrx, Inc. (INBX) Average ROE

How has INBX ROE performed in the past?

The current ROE of Inhibrx, Inc. (INBX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Inhibrx, Inc. (INBX) ROE vs. Peers

How is INBX’s ROE compared to its peers?

Inhibrx, Inc.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Merus N.V. (-36.33%), greater than Lyell Immunopharma, Inc. (-33.35%), greater than Kronos Bio, Inc. (-68.82%), less than Opthea Limited (360.05%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Merrimack Pharmaceuticals, Inc. (-35.28%), greater than Celcuity Inc. (-60.83%), greater than Enliven Therapeutics, Inc. (-29.31%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Design Therapeutics, Inc. (-18.48%), greater than Werewolf Therapeutics, Inc. (-48.25%), greater than Ikena Oncology, Inc. (-42.81%), greater than Stoke Therapeutics, Inc. (-57.89%), less than Protagonist Therapeutics, Inc. (85.47%), greater than DICE Therapeutics, Inc. (-102.37%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Viridian Therapeutics, Inc. (-49.65%),

Build a custom stock screener for Inhibrx, Inc. (INBX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Inhibrx, Inc. (INBX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Inhibrx, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.